The mission of the delegation: to move chromium trioxide from Annex 14 of REACH (substances subject to authorization) to Annex 17 (restricted substances). The meeting came about as a result of an agreement with Dr. Sharon McGuinness, Executive Director of ECHA, in February 2023. It had been agreed to exchange views on emerging relevant topics.
During the meeting, it emerged that both parties had similar views on many aspects of the upcoming challenge. They agreed that this task offers great potential for improvement for authorities and industry and agreed that an analysis of the causes of the exclusive failure of the authorization approach for chromium trioxide is necessary. Neither side saw a fundamental problem with the authorization process or the ECHA's procedures. The CETS Executive Committee will continue to monitor the issue and follow it as closely as possible. For its part, ECHA will carry out initial preliminary work on a proposal that will lead to a call for evidence.